Alan Colowick

Alan Colowick is a seasoned professional currently serving as Managing Director at Matrix Capital Management Company, L.P. since April 2021. In addition, Colowick holds multiple board member positions at various companies, including ReCode Therapeutics, Alumis, ACELYRIN, INC., AC Immune, Harpoon Therapeutics, XyloCor Therapeutics, and InCarda Therapeutics. Previously, Colowick was a board member at Personalis, Inc. from May 2019 to June 2023 and held the role of Partner/Executive Partner at Sofinnova from May 2017 to January 2021. Colowick's educational background includes a medical education at Stanford University School of Medicine and a Master of Public Health in Decision Sciences from Harvard T.H. Chan School of Public Health.